Brief: Biological Efficacy Demonstrated In A Phase 2 Clinical Trial Of Sgx945 For The Treatment Of Behçet's Disease
31/07/2025 13:33
July 31 (Reuters) - Soligenix Inc SNGX.O: BIOLOGICAL EFFICACY DEMONSTRATED IN A PHASE 2 CLINICAL TRIAL OF SGX945 FOR THE TREATMENT OF BEHÇET'S DISEASE SOLIGENIX INC - SGX945 WELL-TOLERATED WITH NO ADVERSE EVENTS Source text: ID:nPncdgnlGa Further company coverage: SNGX.O ((Reuters.Briefs@thomsonreuters.com;))